Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02700776 · ClinicalTrials.gov registry record
1380GCC: Prospective Study of GP-88 Blood Test in Healthy Women With Baseline Gail Model Risk Assessment Undergoing Screening for Breast Cancer
A clinical trial, sponsored by University of Maryland, Baltimore.
- Terminated
- Registry status
- 417
- Enrollment target
NCT02700776: Clinical Trial study, sponsored by University of Maryland, Baltimore.
NCT02700776 is a clinical trial that was terminated before completion, run by University of Maryland, Baltimore. The registered enrollment target is 417 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02700776 was terminated before completion, sponsored by University of Maryland, Baltimore.
- TERMINATED
- Registry status
- 417 participants
- Enrollment target
Study Summary
The purpose of this study is find out if a protein level in the blood (called PC Cell Derived Growth Factor or glycoprotein 88 \[GP88\]), combined with standard mammography screening, can help detect breast cancer better than mammography screening alone. Earlier research has shown that a certain glycoprotein 88 (GP88) is higher in women with breast cancer. In this study, investigators will measure the level of GP88 in the blood of healthy women who are having mammography screening for breast cancer. The investigator plans to correlate the results of the mammogram with the GP-88 level.
Primary Outcome
1\. To prospectively determine the GP-88 blood levels in healthy female volunteers who are undergoing routine screening mammography at the UM Breast Center, Baltimore Washington Medical Center and other local breast imaging referral centers and in patients with biopsy-confirmed breast cancer.
Interventions
- OTHER Phlebotomy - Blood sampling for GP88 at MM
- PROCEDURE SOC Tissue biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 417 participants |
| Start Date | 2014-04 |
| Est. Completion | 2017-02-27 |
Why NCT02700776 stopped before completion
NCT02700776 is an observational study that tracks outcomes without assigning an intervention. The registered 417 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Phlebotomy - Blood sampling for GP88 at MM is the first listed.
NCT02700776 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02700776 about?
NCT02700776 is a clinical study titled "1380GCC: Prospective Study of GP-88 Blood Test in Healthy Women With Baseline Gail Model Risk Assessment Undergoing Screening for Breast Cancer". The purpose of this study is find out if a protein level in the blood (called PC Cell Derived Growth Factor or glycoprotein 88 \[GP88\]), combined with standard mammography screening, can help detect breast cancer better than mammography screening alone. Earlier research has shown that a certain gly...
What is the current status of trial NCT02700776?
This trial is currently terminated. The enrollment target is 417 participants. The study started on 2014-04. Estimated completion is 2017-02-27.
What interventions are being tested in trial NCT02700776?
The interventions under investigation include: Phlebotomy - Blood sampling for GP88 at MM (OTHER), SOC Tissue biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT02700776?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06169735 · 417 participants · Phase 4
Does Fluorescence With or Without Indocyanine Green Improve Parathyroid Identification and Preservation
- NCT06699901 · 417 participants
Antibiotic Concentrations After MassivE Transfusion Study
- NCT03135886 · 418 participants · NA
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
- NCT03527537 · 416 participants · Phase 4
Gestational Diabetes and Pharmacotherapy (GAP)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia